NCT02461368

Brief Summary

The investigators compared the results of the ultrasound-guided anterior and posterior approaches to administer glenohumeral steroid injections to patients with primary adhesive capsulitis of the shoulder joint by a single experienced provider.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2012

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2013

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2014

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

May 29, 2015

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 3, 2015

Completed
Last Updated

September 22, 2023

Status Verified

September 1, 2023

Enrollment Period

11 months

First QC Date

May 29, 2015

Last Update Submit

September 20, 2023

Conditions

Outcome Measures

Primary Outcomes (5)

  • visual analog scale (VAS) for pain

    0-10, 0: no pain, 10: very severe pain

    initial, Week 3, 7, 13

  • range of motion (ROM)

    degree

    initial, Week 3, 7, 13

  • patient's satisfaction (SAT)

    0-10, 0: not satisfied, 10: very much satisfied

    initial, Week 3, 7, 13

  • American Shoulder and Elbow Surgeons (ASES) shoulder score

    0-100

    initial, Week 3, 7, 13

  • Constant score

    0-100

    initial, Week 3, 7, 13

Secondary Outcomes (1)

  • Accuracy of injection using post-injection X-ray

    within 15 minutes after injection

Study Arms (2)

anterior approach

EXPERIMENTAL

Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).

Procedure: Glenohumeral triamcinolone injection by anterior approach

posterior approach

ACTIVE COMPARATOR

Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).

Procedure: Glenohumeral triamcinolone injection by posterior approach

Interventions

Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).

anterior approach

Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).

posterior approach

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • shoulder pain and limitations of active and passive motion in at least two directions (abduction and forward flexion \< 100, external rotation \< 30, or internal rotation \< L3) on the pre-injection check-up
  • those who underwent MRI or ultrasonography with no secondary cause for adhesive capsulitis, such as a rotator cuff tear, calcific tendinitis, or osteoarthritis

You may not qualify if:

  • history of fracture or operation on the affected shoulder
  • loss to follow-up before 13 weeks after the injection
  • receiving another treatment that was different from our protocol within 13 weeks after the injection
  • no functional scores within 13 weeks after the injection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chuncheon Sacred Heart Hospital

Chuncheon, Gangwon-do, 700-204, South Korea

Location

MeSH Terms

Conditions

Bursitis

Condition Hierarchy (Ancestors)

Joint DiseasesMusculoskeletal Diseases

Study Officials

  • Jung-Taek Hwang, MD, PhD

    Chuncheon Sacred Heart Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

May 29, 2015

First Posted

June 3, 2015

Study Start

December 1, 2012

Primary Completion

November 1, 2013

Study Completion

February 1, 2014

Last Updated

September 22, 2023

Record last verified: 2023-09

Locations